TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Mibefradil (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Cavion; Jazz Pharmaceuticals Inc
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 30 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Mar 2018.